# Improving ObsQoR-11 With Continuous Wound Infusion Versus Intrathecal Morphine After Elective Cesarean Delivery

> **NCT05696678** · NA · WITHDRAWN · sponsor: **Ciusss de L'Est de l'Île de Montréal**

## Conditions studied

- Quality of Recovery
- Anesthesia
- Postoperative Pain
- Cesarean Section

## Interventions

- **DRUG:** Intrathecal Morphine
- **DRUG:** Ropivacaine 0.2%

## Key facts

- **NCT ID:** NCT05696678
- **Lead sponsor:** Ciusss de L'Est de l'Île de Montréal
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-02
- **Primary completion:** 2023-08
- **Final completion:** 2023-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The PI has permanently left the institution
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05696678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05696678, "Improving ObsQoR-11 With Continuous Wound Infusion Versus Intrathecal Morphine After Elective Cesarean Delivery". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05696678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*